Close
Nordic 9Nordic 9

EcoR1 Capital (investor - Private Equity)

United States ecor1cap.com
See something wrong or missing? Let us know
Offices:San Francisco

EcoR1 Capital LLC is a biotech-focused investment advisory firm established in 2013 by Oleg Nodelman.

Average round investment:110.11M USD
Average number per year:1.0
Distribution: 2020 (1)
Portfolio companies: Netherlands Neogene Therapeutics
Mostly invests in: Netherlands Netherlands (1) Biotech (1)

1 tracked investments in:

You need an account to access this feature. Log in or create one from here.

Do you have a question? Talk to us.

Investors with similar profile to EcoR1 Capital

Name Criteria
United Kingdom AstraZeneca
69%
  • Range for average deal size: 100M+ USD
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Common investees countries: Netherlands
  • Average number of deals per year: 1.0
United States Hercules Capital
69%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Common investees countries: Netherlands
  • Average number of deals per year: 1.0
United States Two River
69%
  • Range for average deal size: 100M+ USD
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Common investees countries: Netherlands
  • Average number of deals per year: 1.0
United States Bluebird Ventures
69%
  • Range for average deal size: 100M+ USD
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Common investees countries: Netherlands
  • Average number of deals per year: 1.0
United States venBio Partners
69%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Common investees countries: Netherlands
  • Average number of deals per year: 1.5
Denmark ATP
69%
  • Range for average deal size: 100M+ USD
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Common investees countries: Netherlands
  • Average number of deals per year: 1.6
Sweden IK Investment Partners
69%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Common investees countries: Netherlands
  • Average number of deals per year: 1.6
United Kingdom LGT Lightstone
69%
  • Range for average deal size: 100M+ USD
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Common investees countries: Netherlands
  • Average number of deals per year: 1.7
United Arab Emirates Chimera Investment
69%
  • Range for average deal size: 100M+ USD
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Common investees countries: Netherlands
  • Average number of deals per year: 1.8
Belgium Gimv
69%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Biotech, Health services
  • Similar business models: B2B
  • Common investees countries: Netherlands
  • Average number of deals per year: 2.0
Top